Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics Sep 30, 2019 07:30AM
Histogenics (HSGX) to be Acquired by Ocugen Apr 8, 2019 07:07AM
Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics Apr 8, 2019 07:00AM